MADRIGAL PHARMACEUTICALS, INC. Balance Sheet
MDGL / Health Care|12 years of annual SEC 10-K data (FY2012-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 12 fiscal years. All figures from audited SEC 10-K filings.
MADRIGAL PHARMACEUTICALS, INC. had $1.3B in total assets and $603M in shareholders' equity as of FY2025. Total debt was $340M against $199M in cash, resulting in $141M net debt.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2014 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $198.7M | $100.0M | $99.9M | $331.5M | $36.3M | $54.0M | $46.7M | $57.4M | $148.6M | $19.1M | $148.1K | $81.5M |
| Accounts Receivable | $134.5M | $53.8M | $0 | - | - | - | - | - | - | - | - | - |
| Inventory | $74.8M | $34.1M | $0 | - | - | - | - | - | - | - | - | - |
| Current Assets | $1.2B | $1.0B | $637.3M | $361.4M | $271.7M | $285.2M | $440.2M | $485.2M | $192.0M | $41.2M | $99.3M | $101.4M |
| PP&E (Net) | $1.5M | $2.2M | $1.6M | $601.0K | $851.0K | $1.0M | $1.2M | $227.0K | $301.0K | $3.0K | $1.0M | $1.2M |
| Total Assets | $1.3B | $1.0B | $640.5M | $362.6M | $273.3M | $287.0M | $442.1M | $485.4M | $192.3M | $41.2M | $100.7M | $103.0M |
| Current Liabilities | $310.3M | $169.3M | $118.5M | $115.9M | $76.8M | $46.6M | $25.1M | $8.4M | $10.1M | $4.8M | $30.9M | $23.5M |
| Total Debt | $339.9M | $117.6M | $115.5M | $49.3M | $0 | - | - | - | - | - | - | - |
| Shareholders' Equity | $602.7M | $754.4M | $405.3M | $197.4M | $196.1M | $240.0M | $416.6M | $477.0M | $182.3M | $36.4M | -$42.1M | $75.1M |